Watch our FB Live Videos
For our final Facebook Live production of the 40th Anniversary year, Executive Director Suzanne Robotti and Community Manager Karen Calechman held a virtual Town Hall, answering questions from members about DES and taking a look back at the successes of the past year.
Our November interview was with Dr. Gary Levine, Radiologist and Breast Screening Specialist. DES Action USA Community Manager Karen Calechman interviewed him on November 26, focusing on issues specific to DES Daughters, including the difficulty of finding tumors in women who have dense breast tissue as a result of DES exposure.
Members can access our previous videos, with DES researcher Linda Titus (September); with former Executive Director Fran Howell and former Program Director Kari Christiansen (August); Susan Helmrich, DES Daughter and co-founder of DES Cancer Network (July); Dr. Nita Karnick Lee, an ob/gyn with a specialty in DES and oncology (June); DES and Gender researcher Jacquelyne Luce, PhD (May); with DES lawyer Michael London (April); with author Susan Bell (March); with Peabody Award-winning documentarian Judith Helfand about her movie A Healthy Baby Girl (February); and with Dave Fuehrer, creator of the StupidCancer app. Dave’s team added DES-exposed as one of the communities on the free app (right now, only for iPhone. Android soon.) (January). Click for videos.
CVD Risks for DES Daughters
Cardiovascular disease (CVD) is the number 1 cause of death for all women. So it is particularly concerning that reliable research shows that DES daughters are 67% more likely to have coronary artery disease and twice as likely to have a heart attack. DES daughters, according to the study, have no higher likelihood of stroke. The increase in risk is not correlated with the amount of DES exposure or the timing.
Dr. Rebecca Troisi (et al) recently published a paper in the Endocrine Society’s Journal of Clinical Endocrinology & Metabolism (abstract) that details the study. The participants were part of the US NCI (National Cancer Institute) DES Combined Cohort Follow-Up Study. These families have been followed for decades.
An interesting aspect of the study is that DES is being used to gauge the effect that other common endocrine disruptors are causing for the general population. BPA, often found in plastics, has shown indications in lab animal studies that it might be linked to CVD. Troisi’s studies on DES help to clarify the possible risks. To read about the BPA link, please go to our sister site, MedShadow.org.
DES: A population health tragedy
A DES symposium was held at Boston University and was sponsored by the Maternal and Child Health in Action and Group on Reproductive Health and Rights. Below are videos related to the history of DES and to the ongoing research. For a video of Attorney David Fine speaking about lawsuits related to DES, and for more about the symposium, click here.
1. A History of DES by Kari Christiansen
2. Linda Titus, PhD, MA, Professor in the Departments of Epidemiology and Pediatrics at the Geisel School of Medicine at Dartmouth, explains the current research on DES.
Diethylstilbestrol (DES) was the first synthetic estrogen to be created. Never patented, it was cheap and easy to produce, so DES was made by hundreds of drug companies in the U.S. and around the world. DES was prescribed to millions of pregnant women in the mistaken belief that it could prevent miscarriage. It did not work but instead, DES harmed the mothers, the children born of those pregnancies and possibly the grandchildren and beyond.